Elanco News icon with shot of G'field HQ and an Elanco News overlay
30 July 2020

Elanco Animal Health Reports 2020 Second Quarter Results


Posted by: Colleen Parr Dekker

  • Total Revenue for the second quarter was $586.3 million, a decrease of 25 percent. On a constant currency basis, Total Revenue declined 23 percent primarily due to a reduction in channel inventory and lower demand resulting from the COVID-19 pandemic.
  • Earnings per share (EPS) was $(0.13) (reported), or $0.09 (adjusted).
  • Cash and cash equivalents improved to $1.4 billion as of June 30, 2020, as a result of disciplined operating and capital expense management, improved receivable terms, and the sale of our Australia facility.
  • Bayer Animal Health acquisition remains on track to close at the beginning of August; Antitrust, financing, and pre-close integration milestones are complete.
  • Third Quarter 2020 Revenue expected to be between $660 and $710 million for legacy Elanco, excluding revenue from divestitures and with continued impact from the COVID-19 pandemic, primarily in livestock.

GREENFIELD, Ind. (July 30, 2020) - Elanco Animal Health Incorporated (NYSE: ELAN) today reported its financial results for the second quarter of 2020. The performance reflects the reduction of channel inventory and lower levels of demand resulting from the COVID-19 pandemic. Elanco's innovation, portfolio, and productivity strategy continues to be the focus, and its long-term industry fundamentals and durability remain intact.

To view full Press Release, click here.

Media Contact

Colleen Parr Dekker



Investor Contact

Tiffany Kanaga



Connect with Elanco

Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. © 2020 Elanco.